Pharmafile Logo

News and Press Releases

Groundbreaking myalgic encephalomyelitis study identifies over 250 core genes, shared biology with long COVID, and dozens of drug repurposing opportunities

The study reinforces that ME is a complex multisystemic condition with a clear genetic basis and lays the foundation for future clinical trials that could be faster to recruit and...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 4, 2025

PrecisionLife
info@precisionlife.com
8b Bankside Hanborough Business Park Oxford, OX29 8LJ

Integrated DNA Technologies and Beckman Coulter Life Sciences Partner to Advance Cancer Research Through Automated NGS Workflows

Collaboration aims to equip users with complete NGS solution from sample to answer 12 November 2025 -- Colorado and Indiana, US -- Danaher companies Integrated DNA Technologies (IDT), a global leader in...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: November 12, 2025

Beckman Coulter Life Sciences
Amersham Place Little Chalfonts Amersham, HP7 9NA

EpiCypher Launches Fiber-seq Kit to Democratize Single-Molecule Chromatin Mapping

11 November 2025 -- North Carolina, US -- EpiCypher, a leader in chromatin biology and epigenetics, today announced the launch of its CUTANA Fiber-seq Kit and the exclusive licensing of...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: November 11, 2025

EpiCypher

Synthego Launches High-Performance Molecular Reagents for Clinical and Molecular Diagnostics

10 November 2025 -- California, US -- Synthego, a leading provider of CRISPR solutions, has announced a strategic expansion of its product offerings with the launch of a new portfolio of...

Category: Biotechnology, Other, Pharmaceutical
Posted: November 10, 2025

Synthego
3696 Haven Ave Suite A, Redwood City, CA 94063

Thermo Fisher Scientific Showcases Enhanced Accelerator Drug Development Capabilities and OpenAI Strategic Collaboration at CPHI Frankfurt 2025

Company highlights its global expertise and new and expanded capabilities to help biopharma and biotech customers solve global health challenges 27 October 2025 -- Frankfurt, Germany -- Thermo Fisher Scientific...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 27, 2025

Thermo Fisher Scientific
168 Third Avenue Waltham, MA 02451

Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics

Nabla to receive upfront and research cost payments in double-digit millions and eligible to receive success-based payments that may exceed $1 billion Multi-year partnership deploys Nabla Bio’s AI design and...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 14, 2025

Nabla Bio
bd@nabla.bio
Riverside Technology Center
 840 Memorial Dr
 Cambridge, MA 02139

CRISPR Therapeutics Presents New Preclinical Data for CTX460 Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Editing Platform

Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile The AATD program, CTX460, is the first investigational candidate to emerge from the SyNTase editing platform...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 10, 2025

CRISPR Therapeutics
info@crisprtx.com
105 West First Street South Boston, MA 02127 617-315-4600

Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAV

Results presented today at ESGCT 2025 10 October 2025 -- Paris, France and Lund, Sweden -- Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 10, 2025

Genethon
1 bis, rue de l’Internationale 91000 EVRY-COURCOURONNES

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models 9 October 2025 -- Massachusetts, US -- Editas Medicine, Inc, a pioneering gene editing company,...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 9, 2025

Editas Medicine
info@editasmed.com
11 Hurley Street Cambridge, MA 02141 617.401.9000

Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination

Companies sign definitive agreement following previously announced binding term sheet Transaction to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company Combined company to be renamed MindMaze Therapeutics Holding...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 8, 2025

Relief Therapeutics
contact@relieftherapeutics.com
Avenue de Sécheron 15 1202 Geneva Switzerland

EVERSANA Announces Development of End-to-End AI-Powered Life Sciences Marketing Agency Built on Google Cloud Technology

4 August 2025 -- Illinois, US -- EVERSANA, a leading provider of commercialization services to the global life sciences industry, today launched a groundbreaking pharmaceutical marketing AI agency running on...

Category: Other, Pharmaceutical
Posted: August 4, 2025

Eversana
404 S. Wells Street, Chicago, IL 60607

TriloDocs Ltd Joins Genactis Group

16 March 2025 -- London, UK -- We're excited to share some important news! TriloDocs has recently been acquired by Genactis: a global leader in healthcare research and technology. This...

Category: Clinical Trials, Other, Pharmaceutical
Posted: April 16, 2025

TriloDocs
contact@trilodocs.com
25 WILTON Road | LONDON | UNITED KINGDOM | SW1V 1LW

Phesi launches self-service Investigator Site Profiler solution to enhance precision of investigator site selection

Solution benefits clinical development and medical affairs groups – eliminating 20%-30% of investigator sites where there isn’t sufficient data to ensure performance 2 April 2025 -- Massachusetts, US -- Phesi,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 2, 2025

Phesi
info@phesi.com
East Lyme, Connecticut, US

Yourgene Health Launches IONA Care+ Non-invasive Prenatal Testing Service

Offers expectant parents fully comprehensive prenatal screening test for genetic conditions, including microdeletions 13 February 2025 -- Manchester, UK -- Yourgene Health (part of the Novacyt group of companies), a leading...

Category: Biotechnology, Other, Pharmaceutical
Posted: February 13, 2025

Yourgene Health
info@yourgenehealth.com
Skelton House Lloyd Street North Manchester Science Park M15 6SH United Kingdom

Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors

OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective triple inhibitor of...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 30, 2025

Owkin
https://www.owkin.com/
14/16 Bd Poissonnière, 75009 Paris